PerkinElmer Stock Price, News & Analysis (NYSE:PKI)

PerkinElmer trades on the New York Stock Exchange (NYSE) under the ticker symbol "PKI."

PerkinElmer declared a quarterly dividend on Thursday, July 25th. Stockholders of record on Friday, October 18th will be given a dividend of $0.07 per share on Friday, November 8th. This represents a $0.28 annualized dividend and a dividend yield of 0.34%. The ex-dividend date of this dividend is Thursday, October 17th. View PerkinElmer's Dividend History.

PerkinElmer, Inc. (NYSE:PKI) released its earnings results on Monday, July, 29th. The medical research company reported $1.00 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.01 by $0.01. The medical research company had revenue of $722.50 million for the quarter, compared to analysts' expectations of $729.10 million. PerkinElmer had a net margin of 9.01% and a return on equity of 16.07%. The firm's revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.91 earnings per share. View PerkinElmer's Earnings History.

PerkinElmer is scheduled to release their next quarterly earnings announcement on Wednesday, October 30th 2019. View Earnings Estimates for PerkinElmer.

PerkinElmer will be holding an earnings conference call on Wednesday, October 30th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

PerkinElmer issued an update on its FY19 earnings guidance on Monday, July, 29th. The company provided earnings per share guidance of $4.02-4.07 for the period, compared to the Thomson Reuters consensus estimate of $4.05.

13 analysts have issued 12-month price objectives for PerkinElmer's stock. Their forecasts range from $41.00 to $115.00. On average, they anticipate PerkinElmer's stock price to reach $76.86 in the next year. This suggests that the stock has a possible downside of 7.5%. View Analyst Price Targets for PerkinElmer.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for PerkinElmer in the last year. There are currently 8 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for PerkinElmer.

News articles about PKI stock have trended somewhat negative this week, according to InfoTrie Sentiment. The research group identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. PerkinElmer earned a media sentiment score of -1.5 on InfoTrie's scale. They also gave news articles about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for PerkinElmer.

PerkinElmer saw a increase in short interest during the month of September. As of September 30th, there was short interest totalling 5,070,000 shares, an increase of 6.5% from the August 30th total of 4,760,000 shares. Based on an average trading volume of 687,000 shares, the days-to-cover ratio is presently 7.4 days. Approximately 4.6% of the shares of the stock are short sold. View PerkinElmer's Current Options Chain.

Some companies that are related to PerkinElmer include Agilent Technologies (A), Mettler-Toledo International (MTD), Waters (WAT), Bio-Rad Laboratories (BIO), Bio-Rad Laboratories (BIO.B), Avantor (AVTR), Bruker (BRKR), Coherent (COHR), Horiba (HRIBF), Accelerate Diagnostics (AXDX), Pacific Biosciences of California (PACB), Quanterix (QTRX), Fluidigm (FLDM), Eyepoint Pharmaceuticals (EYPT) and Harvard Bioscience (HBIO).

Based on aggregate information from My MarketBeat watchlists, some companies that other PerkinElmer investors own include Honeywell International (HON), Thermo Fisher Scientific (TMO), Celgene (CELG), Visa (V), Cisco Systems (CSCO), Illumina (ILMN), NVIDIA (NVDA), Citigroup (C), CVS Health (CVS) and General Electric (GE).

PerkinElmer's stock is owned by many different of retail and institutional investors. Top institutional investors include Robecosam AG (0.45%), Artemis Investment Management LLP (0.25%), Assenagon Asset Management S.A. (0.06%), Commerzbank Aktiengesellschaft FI (0.03%), Gulf International Bank UK Ltd (0.03%) and State of Alaska Department of Revenue (0.02%). Company insiders that own PerkinElmer stock include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Frank Anders Wilson, James Corbett, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett, Prahlad R Singh and Robert F Friel. View Institutional Ownership Trends for PerkinElmer.

PKI stock was sold by a variety of institutional investors in the last quarter, including First Citizens Bank & Trust Co., Tributary Capital Management LLC, Artemis Investment Management LLP, State of Alaska Department of Revenue, Gulf International Bank UK Ltd, West Oak Capital LLC and Crossmark Global Holdings Inc.. Company insiders that have sold PerkinElmer company stock in the last year include Alexis P Michas, Andrew Okun, Daniel R Tereau, Deborah A Butters, Joel S Goldberg, Nicholas A Lopardo, Patrick J Sullivan, Peter Barrett and Prahlad R Singh. View Insider Buying and Selling for PerkinElmer.

PKI stock was bought by a variety of institutional investors in the last quarter, including Robecosam AG, Assenagon Asset Management S.A., Robeco Institutional Asset Management B.V., Commerzbank Aktiengesellschaft FI, Peddock Capital Advisors LLC, Fox Run Management L.L.C., Pacer Advisors Inc. and Envestnet Asset Management Inc.. View Insider Buying and Selling for PerkinElmer.

Shares of PKI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of PKI stock can currently be purchased for approximately $83.10.

PerkinElmer has a market capitalization of $9.23 billion and generates $2.78 billion in revenue each year. The medical research company earns $237.93 million in net income (profit) each year or $3.61 on an earnings per share basis. PerkinElmer employs 12,500 workers across the globe.View Additional Information About PerkinElmer.

The official website for PerkinElmer is http://www.perkinelmer.com/.

PerkinElmer's mailing address is 940 WINTER STREET, WALTHAM MA, 02451. The medical research company can be reached via phone at 781-663-6900 or via email at [email protected]